Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites

被引:92
|
作者
Ryves, WJ
Dajani, R
Pearl, L
Harwood, AJ
机构
[1] UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England
[2] Inst Canc Res, CRC, Sect Struct Biol, London SW3 6JB, England
基金
英国惠康基金;
关键词
dual inhibition analysis; inhibition; GSK-3; cdc2; MAP kinase 2; lithium; beryllium; magnesium; ATP; ADP;
D O I
10.1006/bbrc.2001.6305
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lithium inhibits (Li(+)) glycogen synthase kinase-3 (GSK-3) by competition for magnesium (Mg(2+)), but not ATP or substrate. Here, we show that the group II metal ion beryllium (Be(2+)) is a potent inhibitor of GSK-3 and competes for both Mg(2+) and ATP. Be(2+) also inhibits the related protein kinase cdc2 at similar potency, but not ALAP kinase 2. To compare the actions of Li(+) and Be(2+) on GSK-3, we have devised a novel dual inhibition analysis. When Be(2+) and ADP are present together each interferes with the action of the other, indicating that both agents inhibit GSK-3 at the ATP binding site. In contrast, Li(+) exerts no interference with ADP inhibition or vice versa. We find, however, that Li(+) and Be(2+) do interfere with each other. These results suggest that Be(2+) competes for two distinct Mg(2+) binding sites: one is Li(+)-sensitive and the other, which is Li(+)-insensitive, binds the Mg:ATP complex. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:967 / 972
页数:6
相关论文
共 50 条
  • [1] Lithium inhibits glycogen synthase kinase-3 by competition for magnesium
    Ryves, WJ
    Harwood, AJ
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 280 (03) : 720 - 725
  • [2] In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3
    Gould, TD
    Chen, G
    Manji, HK
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 (01) : 32 - 38
  • [3] Inhibition of glycogen synthase kinase-3: a potential therapeutic target of lithium
    Jope, RS
    CLINICAL NEUROSCIENCE RESEARCH, 2004, 4 (3-4) : 171 - 179
  • [4] Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3
    Hong, M
    Chen, DCR
    Klein, PS
    Lee, VMY
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) : 25326 - 25332
  • [5] In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3
    Todd D Gould
    Guang Chen
    Husseini K Manji
    Neuropsychopharmacology, 2004, 29 : 32 - 38
  • [6] INHIBITION OF GLYCOGEN-SYNTHASE KINASE-3 BY POLYCATIONS
    HEGAZY, MG
    SCHLENDER, KK
    WILSON, SE
    REIMANN, EM
    FASEB JOURNAL, 1988, 2 (04): : A596 - A596
  • [7] QSAR modeling of the inhibition of Glycogen Synthase Kinase-3
    Katritzky, Alan R.
    Pacureanu, Liliana M.
    Dobchev, Dimitar A.
    Fara, Dan C.
    Duchowicz, Pablo R.
    Karelson, Mati
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (14) : 4987 - 5002
  • [8] Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo
    Noble, W
    Planel, E
    Zehr, C
    Olm, V
    Meyerson, J
    Suleman, F
    Gaynor, K
    Wang, L
    LaFrancois, J
    Feinstein, B
    Burns, M
    Krishnamurthy, P
    Wen, Y
    Bhat, R
    Lewis, J
    Dickson, D
    Duff, K
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (19) : 6990 - 6995
  • [9] CREB DNA binding activity is inhibited by glycogen synthase kinase-3β and facilitated by lithium
    Grimes, CA
    Jope, RS
    JOURNAL OF NEUROCHEMISTRY, 2001, 78 (06) : 1219 - 1232
  • [10] Lithium potentiates insulin signaling. Implications to inhibition of glycogen synthase kinase-3
    Eldar-Finkelman, H
    Carmody, L
    DIABETOLOGIA, 2000, 43 : A162 - A162